Board Appointment

Poolbeg Pharma PLC
24 May 2023
 

Poolbeg Pharma plc

 

Board Appointment

 

24 May 2023 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, 'Poolbeg' or the 'Company'), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, announces the appointment of Brendan Buckley as an Independent Non-Executive Director of the Company with immediate effect. Brendan will also replace Cathal Friel as a member of the Remuneration Committee.

 

Professor Buckley is the former Chief Medical Officer of ICON plc, a medical graduate of University College Cork and a doctoral graduate in Biochemistry in the Faculty of Medicine at Oxford University. Prof Buckley has advised Poolbeg since inception and has deep experience in metabolic diseases including over 40 years' experience in clinical practice as a Consultant Physician in endocrinology, diabetes and in academic clinical pharmacology. Brendan was a member of the Board of Directors of the Irish Medicines Board (now the Health Products Regulatory Authority), chairing its statutory Advisory Committee for Human Medicines. He was also a member of the European Medicines Agency Committee for Orphan Medicinal Products (COMP) and of the European Medicines Agency Scientific Advisory Committee on diabetes and metabolism. Brendan has published over 150 scientific papers, mainly on metabolic disease, as well as the recent key opinion-leading book 'Re-Engineering Clinical Trials'.

 

Jeremy Skillington, PhD, CEO of Poolbeg Pharma, said: "We are delighted to have Brendan join the Board of Directors. His significant contribution to Poolbeg during his role as a member of the Scientific Advisory Board, and his considerable industry experience will be of tremendous benefit as we continue to pursue our goal of becoming a one-stop-shop for pharma and biotechs seeking products to in-license."

 

Brendan Buckley, Non-Executive Director of Poolbeg Pharma, said:" I am honoured to be joining the Board at this exciting time of the Company's development. Poolbeg has a unique model and pipeline and I look forward to working alongside such a strong Management Team targeting a number of growing markets."

 

Regulatory Disclosures

 

The following disclosures are required under Schedule Two, paragraph (g) of the AIM Rules for Companies:

 

Mr Brendan Mary Buckley, aged 73, has held the following directorships and/or partnerships in the past five years:

 

Current directorships:

 

·      hVIVO plc

·      FIGHTING BLINDNESS

·      DS BIOPHARMA LIMITED

·      Afimmune Limited

·      Open Orphan DAC

·      Imutex Ltd

 

Past directorships:

 

·      BREAKTHROUGH CANCER RESEARCH

·      Alliance for Clinical Research Excellence and Safety Inc.

 

Mr Buckley has a beneficial interest in 2,631,474 ordinary shares of the Company representing approximately 0.5 per cent. of the total voting rights.

 

 

- Ends -

 

Enquiries

Poolbeg Pharma Plc

Jeremy Skillington, CEO

Ian O'Connell, CFO

 

+44 (0) 207 183 1499

finnCap Ltd (Nominated Adviser & Joint Broker)

Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM)

 

+44 (0) 207 220 0500

Singer Capital Markets (Joint Broker)

Phil Davies, Sam Butcher

 

 +44 (0) 207 496 3000

J&E Davy (Joint Broker)

Anthony Farrell, Niall Gilchrist

 

+353 (0) 1 679 6363

Optimum Strategic Communications

Nick Bastin, Hana Malik, Vici Rabbetts 

 

+44 (0) 208 078 4357

poolbeg@optimumcomms.com

 

About Poolbeg Pharma

 

Poolbeg Pharma specialises in the development of innovative medicines to address the unmet need in infectious and other prevalent diseases. Poolbeg has a disciplined portfolio approach to mitigate risk, accelerate drug development, and enhance investor returns. The Company simultaneously advances multiple programmes in cost-effective clinical trials, rapidly generating early human safety and efficacy data to enable early partnering / out-licensing, with the funds generated reinvested in the pipeline. Poolbeg also uses AI to interrogate human challenge trial data sets to quickly identify new targets and drugs, and in-license near or in the clinic medicines, leading to faster development and greater commercial appeal.

 

The Company is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest growing pharma markets and is expected to exceed $250bn by 2025. Through opportunistic identification of assets which complement Poolbeg's existing pipeline, the Company is progressing programmes in oncology and metabolic syndromes; adding disease areas with significant addressable markets.

 

With its initial assets from hVIVO plc (formerly Open Orphan plc), an industry leading infectious disease and human challenge trials business, Poolbeg has access to knowledge, experience, and clinical data from over 20 years of human challenge trials. The Company is using these insights to acquire new assets as well as reposition clinical stage products, reducing spend and risk. Amongst its portfolio of exciting assets, Poolbeg has a small molecule immunomodulator for severe influenza and other acute inflammatory conditions (POLB 001) which produces a highly significant reduction in p38 MAP kinase driven cytokines in a clinical setting; a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections (POLB 002); and a vaccine candidate for Melioidosis (POLB 003). The Company is also developing two Oral Delivery Programmes and is progressing two Artificial Intelligence (AI) Programmes to add promising new assets to its pipeline.

 

For more information, please go to www.poolbegpharma.com or follow us on Twitter and LinkedIn @PoolbegPharma.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100